Search results for "tips"

showing 10 items of 280 documents

Phencyclidine-induced disruption of oscillatory activity in prefrontal cortex: Effects of antipsychotic drugs and receptor ligands

2016

The non-competitive NMDA receptor (NMDA-R) antagonist phencyclidine (PCP) markedly disrupts thalamocortical activity, increasing excitatory neuron discharge and reducing low frequency oscillations (LFO, <4Hz) that temporarily group neuronal discharge. These actions are mainly driven by PCP interaction with NMDA-R in GABAergic neurons of the thalamic reticular nucleus and likely underlie PCP psychotomimetic activity. Here we report that classical (haloperidol, chlorpromazine, perphenazine) and atypical (clozapine, olanzapine, quetiapine, risperidone, ziprasidone, aripripazole) antipsychotic drugs - but not the antidepressant citalopram - countered PCP-evoked fall of LFO in the medial prefron…

Male0301 basic medicineOscillationsmedicine.drug_classDopamine AgentsAtypical antipsychoticPhencyclidineKainate receptorPharmacologyNeurotransmissionPrefrontal cortex03 medical and health scienceschemistry.chemical_compoundSerotonin Agents0302 clinical medicineHistamine AgentsmedicineAnimalsPharmacology (medical)NMDA receptor antagonistsAntipsychotic drugsRats WistarChlorpromazineEvoked PotentialsPhencyclidineBiological PsychiatryPharmacologyRacloprideAnalysis of VarianceDose-Response Relationship DrugFourier AnalysisChemistryElectroencephalographyPsychotomimeticRatsPsychiatry and Mental health030104 developmental biologyNeurologynervous systemSchizophreniaNBQXNeurology (clinical)Excitatory Amino Acid AntagonistsNeuroscience030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drug
researchProduct

Phencyclidine inhibits the activity of thalamic reticular gamma-aminobutyric acidergic neurons in rat brain.

2014

Póster presentado en el IX Simposi de Neurobiologia Experimental, celebrado los días 22 y 23 de octubre de 2014 en Barcelona y organizado por la Societat Catalana de Biologia del Institut d'Estudis Catalans

MaleAction PotentialsPhencyclidinePrefrontal CortexLocal field potentialGABA AntagonistsThalamusthalamocortical networksNeural PathwaysmedicinePremovement neuronal activityAnimalsNMDA receptor antagonistsAntipsychotic drugsGABAergic NeuronsRats WistarPrefrontal cortexReceptorPhencyclidineClozapineBiological PsychiatryClozapineAnalysis of VarianceChemistryRatsschizophreniaElectrophysiologyParvalbuminspsychotic symptomsExcitatory postsynaptic potentialHallucinogensNeurosciencemedicine.drugBiological psychiatry
researchProduct

Oral lichenoid drug reaction by lithium in a patient with bipolar disorder

2005

Bipolar disorder (BD) is a psychiatric disease characterized by recurrent and alternated episodes of depression and mania. For the treatment of BD, anticonvulsants drugs as lithium, carbamazepine and oxcarbazepine can be used. These drugs can be associated with potential adverse effects: weight gain, tremors, thyroid abnormalities, and cognitive, gastrointestinal, cardiac or dermatological problems. We describe a case of BD with oral lichenoid drug reaction probably because of the mood stabilizers.

MaleCancer Researchmedicine.medical_specialtyBipolar DisorderLichenoid EruptionsLithium (medication)antipsychotics bipolar disorders drug reaction lichenoid lesions lithium therapyPathology and Forensic Medicinechemistry.chemical_compoundLithium CarbonateAntimanic Agentsmental disordersmedicineHumansBipolar disorderOxcarbazepineAdverse effectbusiness.industryLithium carbonateCarbamazepineMiddle Agedmedicine.diseaseDermatologySurgeryOtorhinolaryngologychemistryLichenoid eruptionPeriodonticsOral Surgerymedicine.symptomMouth DiseasesbusinessManiamedicine.drugJournal of Oral Pathology and Medicine
researchProduct

Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice

2000

Distinguishing the specific effects of neuroleptics on one particular behaviour from its non-specific effects on motility is not easy. In this study, the effects of five neuroleptics on spontaneous motor activity were compared and the ED(50) values of these drugs to impair activity were calculated. Male and female mice were evaluated in an actimeter or in a shuttle-box used as an open field after the administration of chlorpromazine (0.4, 1.2, 3.6 mg/kg), haloperidol (0.1, 0.3, 0.9 mg/kg), raclopride (0.1, 0.3, 0.9 mg/kg), sulpiride (10, 30, 90 mg/kg) and clozapine (0.4, 1.2, 3.6 mg/kg), and two automatic and two observational activity measures were obtained. A very high correlation between…

MaleChlorpromazineMotor ActivityPharmacologyOpen fieldMiceHaloperidolAnimalsMedicinePotencyPharmacology (medical)Motor activityChlorpromazineClozapineBiological PsychiatryClozapinePharmacologyRaclopridebusiness.industryPsychiatry and Mental healthNeurologyRacloprideHaloperidolFemaleNeurology (clinical)SulpiridebusinessSulpirideAntipsychotic Agentsmedicine.drugEuropean Neuropsychopharmacology
researchProduct

The Higher the Dose, the Greater the Sex Differences in Escape–Avoidance Response in Mice After Acute Administration of Haloperidol

1998

Abstract MONLEON, S. AND A. PARRA. The higher the dose, the greater the sex differences in escape–avoidance response in mice after acute administration of haloperidol . PHARMACOL BIOCHEM BEHAV 60 (1) 279–284, 1998.—Sex differences in the effects of haloperidol in the escape–avoidance response have previously been found in various studies carried out in our laboratory in which mice were used as experimental subjects. Males were more affected than females by the disruptive effects of this neuroleptic of frequent clinical use. In the present work these sex differences were evaluated in a unique training session using several doses of the drug (0.075, 0.25, and 0.75 mg/kg IP). The number of avo…

MaleClinical BiochemistryDose dependencePhysiologyMotor ActivityAvoidance responseToxicologyPositive correlationBiochemistryDevelopmental psychologyMiceBehavioral NeuroscienceEscape ReactionAvoidance LearningHaloperidolmedicineAnimalsMotor activityBiological PsychiatryPharmacologySex CharacteristicsDose-Response Relationship DrugAntagonistHaloperidolFemalePsychologyAntipsychotic Agentsmedicine.drugPharmacology Biochemistry and Behavior
researchProduct

Dose-Related Concentrations of Neuroactive/Psychoactive Drugs Expected in Blood of Children and Adolescents

2020

PURPOSE Therapeutic drug monitoring is highly recommended for children and adolescents treated with neurotropic/psychotropic drugs. For interpretation of therapeutic drug monitoring results, drug concentrations (C/D) expected in a "normal" population are helpful to identify pharmacokinetic abnormalities or nonadherence. Using dose-related concentration (DRC) factors obtained from pharmacokinetic data, C/D ranges expected under steady state can be easily calculated by multiplication of DRC by the daily dose. DRC factors, however, are defined only for adults so far. Therefore, it was the aim of this study to estimate DRC factors for children and adolescents and compare them with those of adul…

MaleDrugTopiramatePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentmedia_common.quotation_subjectPopulation030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsparasitic diseasesHumansMedicinePharmacology (medical)ChildeducationAntipsychoticOxcarbazepinemedia_commonPharmacologyeducation.field_of_studyDose-Response Relationship Drugmedicine.diagnostic_testbusiness.industryAge FactorsArea under the curveAntidepressive AgentsTherapeutic drug monitoringArea Under CurveAnticonvulsantsCentral Nervous System StimulantsFemaleDrug MonitoringbusinessAntipsychotic AgentsHalf-Lifemedicine.drugTherapeutic Drug Monitoring
researchProduct

The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey

2008

AbstractThis study related clinical effects to daily doses and serum concentrations of ziprasidone by retrospective analysis of data from a therapeutic drug monitoring (TDM) survey established for patients treated with the new antipsychotic drug. In the total sample of 463 patients ziprasidone doses ranged between 20 and 320 mg/d and correlated significantly (r2 = 0.093, P &lt; 0.01) with serum concentrations. The latter were highly variable within and between individual patients (between patients median 67 ng/ml, 25–75th percentile 40–103 ng/ml). Pharmacokinetic interactions with comedication played a minor role. According to the clinical global impressions (CGI) scale most of the 348 pati…

MaleDrugmedicine.drug_classmedia_common.quotation_subjectAtypical antipsychotic030204 cardiovascular system & hematologyPharmacologySeverity of Illness Index030226 pharmacology & pharmacyDrug Administration SchedulePiperazines03 medical and health sciences0302 clinical medicinePharmacotherapyPharmacokineticsHumansMedicineZiprasidoneRetrospective Studiesmedia_commonDose-Response Relationship Drugmedicine.diagnostic_testMood Disordersbusiness.industryDrug interactionThiazolesPsychiatry and Mental healthTreatment OutcomePsychotic DisordersTherapeutic drug monitoringAnesthesiaPharmacodynamicsDrug Therapy CombinationFemaleDrug MonitoringbusinessAntipsychotic Agentsmedicine.drugEuropean Psychiatry
researchProduct

The family-oriented Open Dialogue approach in the treatment of first-episode psychosis : nineteen–year outcomes

2018

Open Dialogue (OD) is a family-oriented early intervention approach which has demonstrated good outcomes in the treatment of first-episode psychosis (FEP). Nevertheless, more evidence is needed. In this register-based cohort study the long-term outcomes of OD were evaluated through a comparison with a control group over a period of approximately 19 years. We examined the mortality, the need for psychiatric treatment, and the granting of disability allowances. Data were obtained from Finnish national registers regarding all OD patients whose treatment for FEP commenced within the time of the original interventions (total N = 108). The control group consisted of all Finnish FEP patients who h…

MaleFamily therapyPsychological interventionlong-term follow-upwork capabilitylaw.inventionCohort Studies0302 clinical medicineRandomized controlled triallawOutcome Assessment Health CareMedicinetyökykyRegistriesFinlanddisability pensionperheterapiaMiddle AgedPsychiatry and Mental healthSchizophreniaFemalefamily therapyseurantatutkimusCohort studyAdultkuolleisuusmedicine.medical_specialtyAdolescentYoung Adult03 medical and health sciencesEarly Medical InterventionFirst episode psychosisHumansPsychiatryBiological PsychiatryAgedskitsofreniabusiness.industryDisability pensionmedicine.diseasemortalityta3124030227 psychiatryschizophreniaantipsychoticshospital admissionPsychotic DisorderstyökyvyttömyyseläkkeetObservational studybusiness030217 neurology & neurosurgeryPsychiatry Research
researchProduct

Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.

2013

Introduction Aripiprazole, an atypical antipsychotic drug with mixed antagonism and agonism on dopamine D2 and serotonin receptors, is a substrate of the efflux transporter P-glycoprotein (P-gp). Here we tested the pharmacodynamic consequences of these properties in a P-gp deficient mouse model by studying the effects of aripiprazole and of ziprasidone on motor coordination. Methods The motor behaviour of wild-type (WT) and P-gp deficient [abcb1ab(-/-)] mice was investigated on a RotaRod. Mice received acute injections of either aripirazole or ziprasidone. For comparison, the dopamine receptor antagonist haloperidol and serotonin receptor ligands buspirone and ketanserin were also applied. …

MaleKetanserinmedicine.drug_classAripiprazoleAtypical antipsychoticPharmacologyMotor ActivityQuinolonesRotarod performance testPiperazinesBuspironeMiceDopamine receptor D2medicineAnimalsPharmacology (medical)ZiprasidoneATP Binding Cassette Transporter Subfamily B Member 1Mice KnockoutChemistryGeneral MedicineBuspironeSerotonin Receptor AgonistsPsychiatry and Mental healthThiazolesDopamine receptorRotarod Performance TestHaloperidolAripiprazoleKetanserinSerotonin Antagonistsmedicine.drugAntipsychotic AgentsPharmacopsychiatry
researchProduct

Effects of risperidone on the acquisition and reinstatement of the conditioned place preference induced by MDMA

2013

Some users of 3,4-methylenedioxymethylamphetamine (MDMA or ecstasy) abuse this drug and/or become concerned about their use. These individuals would benefit greatly from the development of pharmacological strategies to reduce MDMA consumption. We have previously observed that antipsychotics block acquisition and expression of the conditioned place preference (CPP) induced by MDMA, though they do not modify priming-induced reinstatement of MDMA-induced CPP after extinction. In the present study we have evaluated the capacity of the mixed serotonin (5-HT2A)/dopamine (DA D2) antagonist risperidone to block acquisition and reinstatement of MDMA induced-CPP. Adolescent male mice conditioned with…

MaleN-Methyl-34-methylenedioxyamphetamineEcstasyPharmacologyMiceRewardDopamineConditioning Psychologicalmental disordersmedicineAnimalsDrug InteractionsSerotonin Plasma Membrane Transport ProteinsDopamine Plasma Membrane Transport ProteinsRisperidoneDose-Response Relationship DrugGeneral NeuroscienceAge FactorsAntagonistMDMAExtinction (psychology)RisperidoneCorpus StriatumConditioned place preferenceAnimals NewbornHallucinogensSerotoninPsychologypsychological phenomena and processesAntipsychotic Agentsmedicine.drugBrain Research Bulletin
researchProduct